_Tarceva price_Tarceva 13621079267 purchasing agent for Tarceva in India

Pay on delivery, make medicine with conscience, sell fake medicine and kill the whole family. . . . . . . . . .
India Tarceva
Produced by India's largest oncology drug company, it is the latest biological targeted therapy drug for lung cancer. It is a targeted therapy drug that clinical studies have proven to be able to significantly prolong the survival of lung cancer patients. . At the request of cancer patients or their families, this site can purchase Indian Tarceva on their behalf, and it is guaranteed to be original and authentic from India
[Chinese name]
Tarceva
Erlotinib Hydrochloride Tablets
[Product English name]
[Manufacturer]
Indian pharmaceutical factory
[Effects and Indications]
Used for locally advanced or metastatic patients who have failed two or more chemotherapy regimens third-line treatment of non-small cell lung cancer.
[Chemical Composition]
Each tablet contains erlotinib (in the form of erlotinib hydrochloride).
[Pharmacological Actions] The anti-tumor mechanism of
is mainly to inhibit the intracellular phosphorylation of epidermal growth factor tyrosine kinase.
[Drug Interactions]
[Adverse Reactions]
The most common adverse reactions are rash and diarrhea. The incidence rates of rash and diarrhea are % and % respectively. The median appearance time of rash is days, and the median onset time of diarrhea was days. Adverse reactions with an incidence rate greater than % include rash, diarrhea, decreased appetite, fatigue, dyspnea, cough, nausea, infection, vomiting, stomatitis, itching, dry skin, conjunctivitis, keratoconjunctivitis, and abdominal pain. Pulmonary Toxicity There are rare reports of severe interstitial lung disease, even death, in treated patients or in patients with other solid tumors. In randomized controlled studies, the incidence rate was .% and was the same in the treatment and placebo groups. Reported include pneumonia, interstitial pneumonia, interstitial lung disease, bronchiolitis obliterans, pulmonary fibrosis, acute respiratory stress syndrome, and pulmonary effusion. Symptoms occurred from the day after treatment to more than one month, with a median onset time of days. Most patients often have confounding factors, such as previous chemotherapy/radiation therapy, original parenchymal lung disease, lung metastasis or lung infection. When there are new and unexplained pulmonary symptoms, such as dyspnea, cough, fever, etc., examination and evaluation are required. Once diagnosed, continued use should be stopped and appropriate treatment should be taken. Hepatotoxic treatment can cause asymptomatic increases in liver transaminase. Therefore, liver function should be reviewed regularly during treatment, including transaminases, bilirubin, alkaline phosphatase, etc. If liver function damage is severe, the dose should be reduced or the drug should be discontinued. Liver damage is often temporary or accompanied by liver metastasis. Gastrointestinal bleeding is rarely reported and often occurs in patients taking warfarin at the same time. Therefore, patients taking warfarin or other anticoagulants at the same time should monitor their prothrombin time. Geriatric Patients Safety and pharmacokinetics are not significantly different between young and elderly patients; therefore, no dose adjustment is recommended when used in elderly patients.
【Contraindications】
It is prohibited for those allergic to this product and its ingredients.
[Product Specifications]
[Usage and Dosage]
This product must be used under the guidance of doctors with experience in using such drugs, and only in the National Oncology Drug Clinical Trial Base or Class IIIA Hospital use. The recommended dose of erlotinib monotherapy for non-small cell lung cancer is /day, taken at least one hour before or one hour after eating. Continue treatment until disease progression or intolerable toxicity occurs. There is no evidence that patients benefit from continuing treatment after progression.
【Storage Method】
Store at ℃, temperatures between ℃ and ℃ are also acceptable.
[Precautions]
This product must be used under the guidance of doctors with experience in the use of such drugs, and can only be used in the National Oncology Drug Clinical Trial Base or tertiary A hospitals